l -Cysteine-Glutathione Mixed Disulfide, a Novel Bioavailable Sulfhydryl-Modified Glutathione Precursor, Protects against Early Liver Injury Induced by Short-Term Hypercholesterolemia
Chemical Research in Toxicology · 2025
DOI: 10.1021/acs.chemrestox.5c00272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Research in Toxicology, 2025. Verfasst von Laura Martínez-Gili und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Biomedicine, Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Bar…. Hauptthemen laut MEDLINE: Glutathione, Hypercholesterolemia, Cysteine, Glutathione Disulfide. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Centro de Investigaci?n Biom?dica en Red de Enfermedades Hep?ticas y Digestivas, Center for Strategic Scientific Initiatives, National Cancer Institute.
Abstract (Originalsprache)
Oxidative stress contributes to the damage of biological molecules and is linked to the development of multiple diseases, including liver disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD). In mammals, reduced glutathione (GSH) is a pivotal antioxidant that regulates cellular responses to redox imbalances caused by reactive oxygen and nitrogen species. The presence of reduced GSH within mitochondria is especially crucial for preserving the organelle's routine performance by eliminating hydrogen peroxide generated under both physiological and pathological conditions. Cumulative evidence indicates that MASLD is associated with a diminished mitochondrial GSH (mGSH) pool, attributed to alterations in mitochondrial membrane fluidity due to cholesterol accumulation. Therefore, strategies aimed at boosting mGSH may offer therapeutic benefits against MASLD-associated liver injury. This study aims to investigate whether l-cysteine-glutathione disulfide (l-CySSG), a proposed GSH donor and precursor, can effectively restore total and mGSH in vitro and in vivo in mice fed cholesterol-enriched (HC) or methionine-choline-deficient (MCD) diets. Additionally, S-adenosylmethionine (SAM), a compound that serves as both a GSH precursor and a membrane fluidizer, along with N-acetylcysteine (NAC), a GSH precursor by providing cysteine, was used as the control molecules in the study. Our findings show that l-CySSG has great potential as a liver protector, especially due to its good oral bioavailability. Although it does not restore GSH levels in the mitochondria as efficiently as SAM does, l-CySSG can still offer protection against liver damage, possibly through mechanisms that are not yet fully understood. Overall, l-CySSG emerges as a promising alternative for treating conditions related to oxidative stress and mitochondrial dysfunction, paving the way for future research and therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Cellular Biomedicine, Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona 08036, Spain.
- Liver Unit, Hospital Clinic I Provincial de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036, Spain.
- Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid 28029, Spain.
- CORE Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Centre, Hospital Clínic, Barcelona 08036, Spain.
- Center for Drug Design, University of Minnesota, Minneapolis, Minnesota 55455, United States.
- Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, United States.
ORCID-Profile: Laura Martínez-Gili, Herbert T Nagasawa, Sandra Torres
Förderung
- NCI NIH HHS
- Centro de Investigaci?n Biom?dica en Red de Enfermedades Hep?ticas y Digestivas
- Center for Strategic Scientific Initiatives, National Cancer Institute
- Ministerio de Ciencia, Innovaci?n y Universidades
- Agencia Estatal de Investigaci?n
- European Regional Development Fund
- Ag?ncia de Gesti? d'Ajuts Universitaris i de Recerca
- HORIZON EUROPE Health
Zitieren
APA
Martínez-Gili, L., Fucho, R., Caballero, F., Núñez, S., Jaara, H. S., Alarcón-Vila, C., Rico, N., Nagasawa, H. T., García-Ruiz, C., Fernández-Checa, J. C., & Torres, S. (2025). l -Cysteine-Glutathione Mixed Disulfide, a Novel Bioavailable Sulfhydryl-Modified Glutathione Precursor, Protects against Early Liver Injury Induced by Short-Term Hypercholesterolemia. Chemical Research in Toxicology. https://doi.org/10.1021/acs.chemrestox.5c00272
Vancouver
Martínez-Gili L, Fucho R, Caballero F, Núñez S, Jaara HS, Alarcón-Vila C, et al. l -Cysteine-Glutathione Mixed Disulfide, a Novel Bioavailable Sulfhydryl-Modified Glutathione Precursor, Protects against Early Liver Injury Induced by Short-Term Hypercholesterolemia. Chemical Research in Toxicology. 2025. doi:10.1021/acs.chemrestox.5c00272
BibTeX
@article{MartnezGili2025,
author = {Martínez-Gili, Laura and Fucho, Raquel and Caballero, Francisco and Núñez, Susana and Jaara, Hala Saeed and Alarcón-Vila, Cristina and Rico, Naira and Nagasawa, Herbert T and García-Ruiz, Carmen and Fernández-Checa, José C and Torres, Sandra},
title = {l -Cysteine-Glutathione Mixed Disulfide, a Novel Bioavailable Sulfhydryl-Modified Glutathione Precursor, Protects against Early Liver Injury Induced by Short-Term Hypercholesterolemia},
journal = {Chemical Research in Toxicology},
year = {2025},
doi = {10.1021/acs.chemrestox.5c00272}
}
EUVIMED